GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Current Deferred Revenue

Trinity Biotech (Trinity Biotech) Current Deferred Revenue

: $0.00 Mil (As of Sep. 2023)
View and export this data going back to 1995. Start your Free Trial

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Trinity Biotech's current deferred revenue for the quarter that ended in Sep. 2023 was $0.00 Mil.

Trinity Biotech Current Deferred Revenue Historical Data

The historical data trend for Trinity Biotech's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Deferred Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.31 0.29 4.45 0.14 0.11

Trinity Biotech Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Current Deferred Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.11 - - -

Trinity Biotech Current Deferred Revenue Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's Current Deferred Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Trinity Biotech (Trinity Biotech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » Current Deferred Revenue
Comparable Companies
TTOO PMD STRR CHEK SLDX CNTG MYNZ PRPO BIAF XWEL TSE:2309 TMO DHR IQV IDXX XSWX:LONN A MTD ICLR ILMN
Traded in Other Exchanges
TRBA:Germany
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Website
https://www.trinitybiotech.com
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.